Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample

Biological Psychiatry

Volumn 61, Issue 6, 2007, Pages 734-742

  Kraft, Jeffrey B ^a   Peters, Eric J ^a   Slager, Susan L ^b   Jenkins, Greg D ^b   Reinalda, Megan S ^b   McGrath, Patrick J ^c   Hamilton, Steven P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mayo Clinic   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

5 HTTLPR; Association; case control; citalopram; pharmacogenetics; SLC6A4; SNP; STAR*D

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; HAPLOTYPES; HUMANS; LINKAGE (GENETICS); LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; VARIATION (GENETICS);

EID: 33847282339     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.07.017     Document Type: Article

References (47)

1. Arias B., Catalan R., Gasto C., Gutierrez B., and Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-week follow-up study. J Clin Psychopharmacol 23 (2003) 563-567
2. Bacanu S.A., Devlin B., and Roeder K. The power of genomic control. Am J Hum Genet 66 (2000) 1933-1944
3. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
4. Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., and Nickerson D.A. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74 (2004) 106-120
5. Durham L.K., Webb S.M., Milos P.M., Clary C.M., and Seymour A.B. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 174 (2004) 525-529
6. Esposito K., and Goodnick P. Predictors of response in depression. Psychiatr Clin North Am 26 (2003) 353-365
7. Fava M., Rush A.J., Trivedi M.H., Nierenberg A.A., Thase M.E., Sackeim H.A., et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26 (2003) 457-494, x
8. Freidlin B., Zheng G., Li Z., and Gastwirth J.L. Trend tests for case-control studies of genetic markers: Power, sample size and robustness. Hum Hered 53 (2002) 146-152
9. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 296 (2002) 2225-2229
10. Gaynes B.N., Rush A.J., Trivedi M., Wisniewski S.R., Balasubramani G.K., Spencer D.C., et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: Preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 27 (2005) 87-96
11. Ioannidis J.P.A. Why most published research findings are false. PLoS Med 2 (2005)
12. Ito K., Yoshida K., Sato K., Takahashi H., Kamata M., Higuchi H., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111 (2002) 235-239
13. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Miller A.L., Rogers G.R., et al. Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 6 (2003) 339-346
14. Kato M., Ikenaga Y., Wakeno M., Okugawa G., Nobuhara K., Fukuda T., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 20 (2005) 151-156
15. Kim D.K., Lim S.W., Lee S., Sohn S.E., Kim S., Hahn C.G., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuro Report 11 (2000) 215-219
16. Kraft J.B., Slager S.L., McGrath P.J., and Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58 (2005) 374-381
17. Lee M.S., Lee H.Y., Lee H.J., and Ryu S.H. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 14 (2004) 111-115
18. Lesch K.P., and Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1062-1073
19. Licinio J., and Wong M.L. Pharmacogenomics in psychiatry: Clinical issues to be considered. Mol Psychiatry 10 (2005) 615
20. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78 (2006) 804-814
21. Minov C., Baghai T.C., Schule C., Zwanzger P., Schwarz M.J., Zill P., et al. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett 303 (2001) 119-122
22. Murphy Jr. G.M., Hollander S.B., Rodrigues H.E., Kremer C., and Schatzberg A.F. Effects of the serotonin transporter gene promotor polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61 (2004) 1163-1169
23. Ng C.H., Easteal S., Tan S., Schweitzer I., Ho B.K.W., and Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progess in Neuro-Psychopharmacology and Biological Psychiatry 30 (2006) 953-957
24. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., and Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9 (2004) 879-889
25. Pollock B.G., Ferrell R.E., Mulsant B.H., Mazumdar S., Miller M., Sweet R.A., et al. Allelic variation in the serotonin transporter promotor affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23 (2000) 587-590
26. Pritchard J.K., and Rosenberg N.A. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65 (1999) 220-228
27. Quitkin F.M., Rabkin J.D., Markowitz J.M., Stewart J.W., McGrath P.J., et al. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 44 (1987) 259-264
28. Rausch J.L., Johnson M.E., Fei Y.J., Li J.Q., Shendarkar N., Hobby H.M., et al. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 51 (2002) 723-732
29. Ross D.C., Quitkin F.M., and Klein D.F. A typological model for estimation of drug and placebo effects in depression. J Clin Psychopharmacol 22 (2002) 414-418
30. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54 (2003) 573-583
31. Rush A.J., Fava M., Wisniewski S.R., Lavori P.W., Trivedi M.H., Sackeim H.A., et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Controlled Clin Trials 25 (2004) 119-142
32. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
33. Serretti A., and Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 4 (2004) 233-244
34. Serretti A., Artioli P., and Quartesan R. Pharmacogenetics in the treatment of depression: Pharmacodynamic studies. Pharmacogenet Genomics 15 (2005) 61-67
35. Smits K.M., Smits L.J., Schouten J.S., Stelma F.F., Nelemans P., and Prins M.H. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: Systematic review. Mol Psychiatry 9 (2004) 433-441
36. Stewart J.W., Quitkin F.M., McGrath P.J., Amsterdam J., Fava M., Fawcett J., et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 55 (1998) 334-343
37. Tang H., Quertermous T., Rodriguez B., Kardia S.L., Zhu X., Brown A., et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 76 (2005) 268-275
38. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163 (2006) 28-40
39. Wacholder S., Chanock S., Garcia-Closas M., El ghormli L., and Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 96 (2004) 434-442
40. Walsh B.T., Seidman S.N., Sysko R., and Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 287 (2002) 1840-1847
41. Yoshida K., Ito K., Sato K., Takahashi H., Kamata M., Higuchi H., et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japenese depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26 (2002) 383-386
42. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. American Journal of Psychiatry 262 (2004) 1575-1580
43. Yu Y.W., Tsai S.J., Chen T.J., Lin C.H., and Hong C.J. Association study of the serotonin transporter promotor polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7 (2002) 1115-1119
44. Zanardi R., Benedetti F., Di Bella D., Catalano M., and Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promotor of the serotonin transporter gene. J Clin Psychopharmacol 20 (2000) 105-107
45. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and t-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50 (2001) 323-330
46. Zimmerman M., and Mattia J.I. The reliability and validity of a screening Questionnaire for 13 DSM-IV Axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. J Clin Psychiatry 60 (1999) 677-683
47. Zisook S., John Rush A., Albala A., Alpert J., Balasubramani G.K., Fava M., et al. Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res 129 (2004) 127-140